- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Ultrasound-guided optical technique lowers biopsy rate
An ultrasound-guided diffuse optical technique may lower the rate at which women undergo breast biopsies for suspicious lesions, according to a study published in Radiology.
An ultrasound-guided diffuse optical technique may lower the rate at which women undergo breast biopsies for suspicious lesions, according to a study published in Radiology.
Diffuse optical tomography is a noninvasive imaging technique that measures light absorption within tissue to quantify blood content and blood oxygen levels. Once ultrasound locates the lesion, DOT is performed by shining infrared light into the area and measuring light absorption at two optical wavelengths.
In the study, 178 consecutive women underwent the technique on a previously identified solid lesion followed by a biopsy. Researchers computed total hemoglobin levels from the light absorption measured at two wavelengths and correlated the measurements with biopsy results. Tissue sample examinations revealed two in situ carcinomas, 35 carcinomas that measured <2 cm, 24 carcinomas >2 cm, and 114 benign lesions (2010;256:367-378). The sensitivity (92%) and specificity (93%) of the technique were greatest when evaluating cancers <2 cm in size.
DOT holds promise as an adjunct to diagnostic mammography and ultrasound for distinguishing early stage invasive breast cancers from benign lesions, the researchers said.
Multicenter Study Shows Merits of AI-Powered Ultrasound Assessment for Detecting Ovarian Cancer
January 3rd 2025Adjunctive AI offered greater than seven percent increases in sensitivity, specificity, and accuracy for ultrasound detection of ovarian cancer in comparison to unassisted clinicians who lacked ultrasound expertise, according to findings from new international multicenter research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
